Aim: To research the biological effect of the F(ab')(2) of anti-platelet GPIIIa mAb SZ-21.
Methods: The F(ab')(2) fragment was obtained with papain digestion for 20 hours at 4 degrees Celsius, under acid condition(pH 5.5). The products were purified through DEAE-52 ion exchange column and the first eluted peak components were verified as F(ab')(2) by SDS-PAGE. The immunoactivity and its antithrombotic effects of fragment were detected by ELISA and platelet aggregation inhibition test, respectively.
Results: The recovery rate of the fragment was 60.32%, its immunoactivity was 0.8 x10(-9) mol/L by ELISA. The 50% effective dose (ED(50)) in the platelet aggregate inhibition test was 3.395 mg/L.
Conclusion: The F(ab')(2) fragment was superior to intact IgG in binding to platelets and inhibiting platelet aggregation. Thus the F(ab')(2) fragment of mAb SZ-21 opens up broad prospects for its application to the clinical antithrombotic therapy.